

DMG DEUTSCHE MALARIA GmbH

is a lean management company
working with centres of excellence
innovative antimalarial solutions



Become a Partner in One of Our Programs

- A. Treatment for CHILDREN
join us for
„Children Severe Malaria“
- B. Treatment for TRAVELLERS
join us for
„Traveller Africa“
- C. Mosquito Trap
join us for
„Virtual Net“

Ways to join our programs as

Development Partner
Commercial Partner
Licensing Partner
Equity Partner

CONTACT

DMG Deutsche Malaria GmbH
Neuer Wall 72 • 20354 Hamburg, Germany
T +49-40-81 80 28 • M +49-40-172 916 13 66

UK Office:
T +44-1959-56 34 87 • F +44-1959-56 29 31
info@deutschemalaria.com

TEAM UP AGAINST MALARIA

SAVE YOUNG CHILDREN

FIGHT DRUG RESISTANCE

HELP DEVELOP AFRICA

**DMG DEUTSCHE MALARIA GMBH
HAMBURG, GERMANY**

**FIRST GERMAN COMPANY TO
DEVELOP A RELEVANT ANTIMALARIA
THERAPY AFTER 80 YEARS**

FOCUS ON CHILDREN

When 1000 people die from malaria
800 are children under five.

Novel drug combinations are developed by
us to be

safe for children

well tolerated by children

highly effective in children

FOCUS ON DRUG RESISTANCE

Malaria is not defeated yet.
WHO reported an increase in 2016.

Artemisinin resistance is documented in the
Mekong Region, in China, Bangladesh,
India and first cases in Africa.

Most first and second line therapies today
rely on artemisinin derivatives.

At DEUTSCHE MALARIA we see an urgent
need for our non-artemisinin approach.

FOCUS ON AFRICA

There are too many malaria deaths in Africa.
THAT MUST BE CHANGED.

Economic progress is hampered by malaria.
THAT CAN BE CHANGED.

Fosmidomycin is a natural compound originally
isolated from *Streptomyces* microorganisms.
Today it is chemically synthesised.

Mode of action: blocking a vital metabolic
pathway of the parasite that is absent in
humans. It has no biochemical target in the
human body and therefore no measurable side
effects.

In Combination with PIPERAQUINE

Combines rapidity of action and protection
against recrudescence infections and has been
clinically tested (Phase IIa).

With AQ13

A new compound which has no cross-
resistance with piperazine.

With CLINDAMYCIN and ARTESUNATE

Against severe malaria and aims at
treating co-existing bacterial infections.

Early Diagnosis

Stand-by treatment for travellers in
combination with a Rapid Diagnostic Test.

Biological Mosquito Trap

Self-sustaining innovative trap acts as a
„virtual net“. Reduces transmission and
broadens the Company's contribution
towards the elimination of malaria.